Health
Study supports continuing phase 3 trials of Ad26.COV2.S SARS-CoV-2 vaccine – News-Medical.Net
An international team of researchers has provided further evidence to confirm the immunogenicity and efficacy of a recombinant adenovirus vaccine currently being…
An international team of researchers has provided further evidence to confirm the immunogenicity and efficacy of a recombinant adenovirus vaccine currently being tested in phase 3 trials for its ability to protect against infection with severe acute respiratory coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).
The vaccine comprises a recombinant adenovirus serotype 26 (Ad26) vaccine vector expressing a stabilized form of the SARS-CoV-2 spike antigen that the…
-
Business17 hours agoThe pros and cons of buying CBA shares in September
-
Noosa News17 hours agoRent changes on way for hundreds of social housing recipients following government review
-
Noosa News24 hours agoMan charged with murder three days after death of 27-year-old in Livingstone, QLD
-
Business12 hours agoWhere will Berkshire Hathaway be in 1 year?